Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;14(4):778-84.
doi: 10.1007/s10461-009-9533-2. Epub 2009 Mar 13.

Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study

David M Tuller  1 , David R Bangsberg, Jude Senkungu, Norma C Ware, Nneka Emenyonu, Sheri D Weiser
Affiliations

Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study

David M Tuller et al. AIDS Behav. 2010 Aug.

Abstract

The cost of transportation for monthly clinic visits has been identified as a potential barrier to antiretroviral (ARV) adherence in sub-Saharan Africa and elsewhere, although there is limited data on this issue. We conducted open-ended interviews with 41 individuals living with HIV/AIDS and attending a clinic in Mbarara, Uganda, to understand structural barriers to ARV adherence and clinical care. Almost all respondents cited the need to locate funds for the monthly clinic visit as a constant source of stress and anxiety, and lack of money for transportation was a key factor in cases of missed doses and missed medical appointments. Participants struggled with competing demands between transport costs and other necessities such as food, housing and school fees. Our findings suggest that transportation costs can compromise both ARV adherence and access to care. Interventions that address this barrier will be important to ensure the success of ARV programs in sub-Saharan Africa.

PubMed Disclaimer

References

    1. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England) 2000;14(4):357–366. - PubMed
    1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England) 2001;15(9):1181–1183. - PubMed
    1. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS (London, England) 2006;20(1):140–141. - PubMed
    1. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases. 2004;38(Supp 5):S429–S436. doi: 10.1086/421408. - DOI - PubMed
    1. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. International Journal of STD and AIDS. 2005;16(1):38–41. doi: 10.1258/0956462052932548. - DOI - PubMed

Publication types